Myozyme

Myozyme. It is the brand name for alglucosidase alfa, a recombinant form of the human enzyme acid alpha-glucosidase (GAA) used as an enzyme replacement therapy for Pompe disease. Developed by Genzyme Corporation, it was the first specific treatment approved for this rare, progressive, and often fatal lysosomal storage disorder. Its approval by the Food and Drug Administration in 2006 and the European Medicines Agency in 2007 marked a pivotal advancement in the management of this genetic disorder.

Medical uses

Myozyme is indicated for the long-term treatment of patients with a confirmed diagnosis of Pompe disease, which is caused by a deficiency in the GAA enzyme. This deficiency leads to pathological accumulation of glycogen within cellular lysosomes, particularly damaging cardiac muscle, skeletal muscle, and respiratory muscles. Clinical trials, such as those published in the New England Journal of Medicine, demonstrated its efficacy in improving ventilator-free survival in infantile-onset patients and stabilizing or improving motor and respiratory function in late-onset cases. Treatment is administered via regular intravenous infusion and requires management by specialists familiar with metabolic disease.

Adverse effects

The most serious adverse reactions associated with Myozyme are severe anaphylactic and hypersensitivity reactions, which can be life-threatening. Common infusion-associated reactions include pyrexia, rash, tachycardia, tachypnea, vomiting, and hypotension. Due to the risk of severe immune-mediated reactions, patients are often pre-medicated with antihistamines and corticosteroids. The development of antibodies against the therapeutic enzyme, particularly high and sustained titers, can reduce clinical efficacy, a concern noted in regulatory documents from the Food and Drug Administration.

Pharmacology

Alglucosidase alfa is a recombinant human GAA enzyme produced in Chinese hamster ovary cells via biotechnology. Its mechanism of action involves binding to mannose-6-phosphate receptors on the cell surface, leading to cellular uptake and transport to the intracellular lysosomes. Once within the lysosome, the enzyme catalyzes the hydrolysis of glycogen to glucose, thereby reducing the substrate accumulation that characterizes Pompe disease. The pharmacokinetic profile shows a biphasic decline, with a terminal half-life that supports an every-other-week dosing regimen.

History

The development of Myozyme followed decades of research into lysosomal storage disorders, building on foundational work by scientists like Henri G. Hers who characterized the enzyme deficiency. Genzyme Corporation spearheaded its clinical development, with pivotal trials conducted at major centers including Duke University and University Hospital Rotterdam. The drug received orphan drug designation from both the Food and Drug Administration and the European Medicines Agency, facilitating its expedited review. Its approval was a landmark event, often cited alongside other pioneering enzyme therapies like Cerezyme for Gaucher disease.

Society and culture

The introduction of Myozyme had profound societal implications, dramatically altering the prognosis for infantile-onset Pompe disease and bringing significant attention to the challenges of developing treatments for rare diseases. Its high cost sparked international debates on drug pricing and reimbursement, involving entities like the National Health Service in the United Kingdom and Medicare in the United States. The story of its development and the patient community's advocacy were popularized in works like the book *The Cure* by Geeta Anand, and it remains a case study in bioethics, orphan drug policy, and patient access.

Category:Enzymes Category:Orphan drugs Category:Genzyme